Torrent Pharmaceuticals Ltd
Fundamental Score
Torrent Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of TORNTPHARM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (26.52%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.05%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (30.68%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Robust Profit Growth (32.49%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Interest Coverage (14.47x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹10189.41 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.31%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 25.09%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 58.36x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Financial Statements
Comprehensive financial data for Torrent Pharmaceuticals Ltd
About TORNTPHARM
Business Overview
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.
Company Details
Key Leadership
Corporate Events
TORNTPHARM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Torrent Pharmaceuticals Ltd (TORNTPHARM)?
As of 09 Feb 2026, 12:14 pm IST, Torrent Pharmaceuticals Ltd (TORNTPHARM) is currently trading at ₹3997.20. The stock has a market capitalization of ₹1.26L (Cr).
Is TORNTPHARM share price Overvalued or Undervalued?
TORNTPHARM is currently trading at a P/E ratio of 58.36x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Torrent Pharmaceuticals Ltd share price?
Key factors influencing TORNTPHARM's price include its quarterly earnings growth (Sales Growth: 14.30%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Torrent Pharmaceuticals Ltd a good stock for long-term investment?
Torrent Pharmaceuticals Ltd shows a 5-year Profit Growth of 13.84% and an ROE of 26.52%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.33 before investing.
How does Torrent Pharmaceuticals Ltd compare with its industry peers?
Torrent Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare TORNTPHARM's P/E of 58.36x and ROE of 26.52% against the industry averages to determine its competitive standing.
What is the P/E ratio of TORNTPHARM and what does it mean?
TORNTPHARM has a P/E ratio of 58.36x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹58 for every ₹1 of annual earnings.
How is TORNTPHARM performing according to Bull Run's analysis?
TORNTPHARM has a Bull Run fundamental score of 65.3/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does TORNTPHARM belong to?
TORNTPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Torrent Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for TORNTPHARM?
TORNTPHARM has an ROE of 26.52%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Torrent Pharmaceuticals Ltd generates profits from shareholders' equity.
How is TORNTPHARM's debt-to-equity ratio and what does it indicate?
TORNTPHARM has a debt-to-equity ratio of 0.33, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is TORNTPHARM's dividend yield and is it a good dividend stock?
TORNTPHARM offers a dividend yield of 0.86%, which means you receive ₹0.86 annual dividend for every ₹100 invested.
How has TORNTPHARM grown over the past 5 years?
TORNTPHARM has achieved 5-year growth rates of: Sales Growth 7.72%, Profit Growth 13.84%, and EPS Growth 13.84%.
What is the promoter holding in TORNTPHARM and why does it matter?
Promoters hold 68.31% of TORNTPHARM shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is TORNTPHARM's market capitalization category?
TORNTPHARM has a market capitalization of ₹126431 crores, placing it in the Large-cap category.
How volatile is TORNTPHARM stock?
TORNTPHARM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for TORNTPHARM?
TORNTPHARM has a 52-week high of ₹N/A and low of ₹N/A.
What is TORNTPHARM's operating profit margin trend?
TORNTPHARM has a 5-year average Operating Profit Margin (OPM) of 30.68%, indicating the company's operational efficiency.
How is TORNTPHARM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 14.30% and YoY Profit Growth of 32.49%.
What is the institutional holding pattern in TORNTPHARM?
TORNTPHARM has FII holding of 15.92% and DII holding of 9.17%. Significant institutional holding often suggests professional confidence in the stock.